Update on the pathogenesis and management of childhood asthma

Current Opinion in Pediatrics

Volumn 20, Issue 5, 2008, Pages 597-604

  Cornell, Alexandra ^a   Shaker, Marcus ^a,b   Woodmansee, Donald R ^a  

^a CHILDREN S HOSPITAL AT DARTMOUTH   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Asthma prevention; Inhaled corticosteroids; Long acting agonists; National asthma education and prevention program expert panel report 3; Predictors of asthma

Indexed keywords

ANTIBIOTIC AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; MONTELUKAST; OMALIZUMAB; PLACEBO; SALMETEROL;

ANTIBIOTIC THERAPY; ASTHMA; ATOPY; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMORBIDITY; DRUG EXPOSURE; DRUG MEGADOSE; GENOTYPE; HUMAN; MONOTHERAPY; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENAL CORTEX HORMONES; ALLERGENS; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHIAL HYPERREACTIVITY; BRONCHODILATOR AGENTS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; INCIDENCE; MALE; PATIENT COMPLIANCE; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RESPIRATORY FUNCTION TESTS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SKIN TESTS; TREATMENT OUTCOME;

EID: 53549083524     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOP.0b013e32830fe40e     Document Type: Review

References (30)

1. Bloom B, Cohen RA. Summary health statistics for U.S. children: National Health Interview Survey, 2006. Vital Health Stat 10 2007:1-79.
2. Martinez FD. Trends in asthma prevalence, admission rates, and asthma deaths. Respir Care 2008; 53:561-565; discussion 5-7.
3. National Heart Lung and Blood Institute. Guidelines for the Diagnosis and Management of Asthma, Expert Panel Report 3. NIH Publication No. 08-4051; 2007. www.nhlbi.nih.gov/guidelines/asthma
4. Alm B, Erdes L, Mollborg P, et al. Neonatal antibiotic treatment is a risk factor for early wheezing. Pediatrics 2008; 121:697-702.
5. Zutavern A, Brockow I, Schaaf B, et al. Timing of solid food introduction in relation to eczema, asthma, allergic rhinitis, and food and inhalant sensitization at the age of 6 years: results from the prospective birth cohort study LISA. Pediatrics 2008; 121:e44-e52.
6. Greer FR, Sicherer SH, Burks AW. Effects of early nutritional interventions on the development of atopic disease in infants and children: the role of maternal dietary restriction, breastfeeding, timing of introduction of complementary foods, and hydrolyzed formulas. Pediatrics 2008; 121:183-191.
7. Celedon JC, Milton DK, Ramsey CD, et al. Exposure to dust mite allergen and endotoxin in early life and asthma and atopy in childhood. J Allergy Clin Immunol 2007; 120:144-149.
8. Arshad SH, Bateman B, Matthews SM. Primary prevention of asthma and atopy during childhood by allergen avoidance in infancy: a randomised controlled study. Thorax 2003; 58:489-493.
9. Taveras EM, Rifas-Shiman SL, Camargo CA Jr, et al. Higher adiposity in infancy associated with recurrent wheeze in a prospective cohort of children. J Allergy Clin Immunol 2008; 121:1161 e3-1166 e3.
10. Israel E, Drazen JM, Liggett SB, et al. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000; 162:75-80.
11. Israel E, Chinchilli VM, Ford JG, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004; 364:1505-1512.
12. Wechsler ME, Lehman E, Lazarus SC, et al. beta-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 2006; 173:519-526.
13. Bleecker ER, Postma DS, Lawrance RM, et al. Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 2007; 370:2118-2125.
14. Tantisira KG, Silverman ES, Mariani TJ, et al. FCER2: a pharmacogenetic basis for severe exacerbations in children with asthma. J Allergy Clin Immunol 2007; 120:1285-1291.
15. Palmer CN, Ismail T, Lee SP, et al. Filaggrin null mutations are associated with increased asthma severity in children and young adults. J Allergy Clin Immunol 2007; 120:64-68.
16. Liu AH, Zeiger R, Sorkness C, et al. Development and cross-sectional validation of the Childhood Asthma Control Test. J Allergy Clin Immunol 2007; 119:817-825.
17. Berry MA, Shaw DE, Green RH, et al. The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma. Clin Exp Allergy 2005; 35:1175-1179.
18. Khalili B, Boggs PB, Bahna SL. Reliability of a new hand-held device for the measurement of exhaled nitric oxide. Allergy 2007; 62:1171-1174.
19. Taylor DR. Nitric oxide as a clinical guide for asthma management. J Allergy Clin Immunol 2006; 117:259-262.
20. Smith AD, Cowan JO, Brassett KP, et al. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005; 352:2163-2173.
21. Pijnenburg MW, Hofhuis W, Hop WC, De Jongste JC. Exhaled nitric oxide predicts asthma relapse in children with clinical asthma remission. Thorax 2005; 60:215-218.
22. Sorkness CA, Lemanske RF Jr, Mauger DT, et al. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial. J Allergy Clin Immunol 2007; 119:64-72.
23. Hendeles L, Sorkness CA. Antiimmunoglobulin E therapy with omalizumab for asthma. Ann Pharmacother 2007; 41:1397-1410.
24. Wu AC, Paltiel AD, Kuntz KM, et al. Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model. J Allergy Clin Immunol 2007; 120:1146-1152.
25. Busse WW, Pedersen S, Pauwels RA, et al. The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5-year follow-up: effectiveness of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol 2008; 121:1167-1174.
26. Szefler SJ, Baker JW, Uryniak T, et al. Comparative study of budesonide inhalation suspension and montelukast in young children with mild persistent asthma. J Allergy Clin Immunol 2007; 120:1043-1050.
27. Ozdemir C, Yazi D, Gocmen I, et al. Efficacy of long-term sublingual immunotherapy as an adjunct to pharmacotherapy in house dust miteallergic children with asthma. Pediatr Allergy Immunol 2007; 18:508-515.
28. Penagos M, Passalacqua G, Compalati E, et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest 2008; 133:599-609.
29. Wenzel S, Wilbraham D, Fuller R, et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007; 370:1422-1431.
30. Cox G, Thomson NC, Rubin AS, et al. Asthma control during the year after bronchial thermoplasty. N Engl J Med 2007; 356:1327-1337.